Houlihan Lokey Advises Laboratoires SERB

Houlihan Lokey is pleased to announce that Laboratoires SERB (SERB), a portfolio company of Charterhouse Capital Partners LLP (Charterhouse), has entered into a definitive agreement to acquire BTG Specialty Pharmaceuticals from Boston Scientific.

SERB is a leading European specialty pharmaceutical group focused on prescription medicines that address rare and life-threatening diseases. Since SERB was backed by Charterhouse in November 2017, it has experienced strong organic and inorganic growth, expanding its direct presence from three to nine countries, integrating seven strategic acquisitions, and doubling its revenues in the process. This latest acquisition will transform the group into a fully integrated specialty pharmaceutical platform that is well positioned for further growth, with around 400 employees based in 11 offices, new manufacturing capabilities, and a direct commercial presence across all major pharmaceutical markets worldwide.

BTG Specialty Pharmaceuticals provides antidotes and rescue medicines that are typically used in emergency rooms and intensive care units to treat patients with critical conditions, and therefore represents an excellent strategic fit for SERB. Its portfolio is manufactured from state-of-the-art facilities and sold worldwide via a dedicated commercial team. It also includes gold-standard brands in the emergency care space such as CroFab, DigiFab, and Voraxaze, which complement SERB’s existing specialty products in critical care and rare diseases.

Charterhouse is one of the longest established private equity firms operating in Europe. It invests with a growth-focused approach to middle-market European companies across the services, healthcare, industrials, and consumer sectors. Charterhouse follows a selective, conviction-led style, sourcing attractive investment opportunities often ahead of any process with the long-term ambition of driving transformational change.

Houlihan Lokey served as the exclusive financing advisor to SERB and Charterhouse in this transaction.